Cambridge, Mass.-based Moderna and Emeryville, Calif.-based Metagenomi inked a strategic research and development deal on new gene editing systems for in vivo (in the body) human therapies.
Teva Pharmaceutical announced positive results from the company’s Phase III trial on a subcutaneous, long-acting injectable risperidone formulation in the treatment of schizophrenia.
Merck is widening the company’s reach into the treatment of autoimmune diseases by investing in Synthekine, a bioresearch company that develops engineered cytokine therapeutics.
Novavax Inc. and partner Serum Institute of India said on November 1 they received emergency use authorization for their Covid-19 vaccine in Indonesia, making it the first approval anywhere in the world for Novavax.
AstraZeneca said on Nov. 1 the company will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million, as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.
The inexpensive antidepressant fluvoxamine might help keep patients with Covid-19 from developing severe disease, according to a study published in The Lancet Global Health. Researchers found in another study that the coronavirus can infect cells of the inner ear, which may help explain the balance problems, hearing loss and tinnitus (ringing in the ears) experienced by some Covid-19 patients.
Alnylam announced that the experimental RNAi drug vutrisiran continues to demonstrate positive results at the 18-month mark in patients diagnosed with polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. AbbVie posted Phase III results from two separate studies assessing Vraylar (cariprazine) as an adjunctive treatment for the major depressive disorder. Vraylar came to AbbVie through the company’s acquisition of Allergan.
A study by The National Institutes for Quantum Science and Technology in Japan found that a supplement with seven specific amino acids called Amino LP7 appeared to slow brain degeneration and dementia development in mice.
AbbVie’s experimental subcutaneous Parkinson’s disease drug ABBV-951 hit the mark in a 12-week Phase III study in patients with an advanced form of the disease.
Cranbury, New Jersey-based Rafael Pharmaceuticals reported disappointing results from two Phase III clinical trials evaluating the safety and efficacy of the cancer metabolism drug CPI-613 (devimistat) when combined with modified FOLFIRINOX (mFFX) as a first-line therapy.
